Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - CNBC
Source:CNBC
Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday.
Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday.